title: [Phase I clinical trial evaluation of capecitabine in concurrent combination of radiotherapy in nasopharyngeal carcinoma].
abstract: OBJECTIVE
  Capecitabine is an oral fluoropyrimidine, which is converted to fluorouracil (5-FU) by exploiting the comparatively higher activity of thymidine phosphorylase (TP) in tumor tissue. This study was designed to measure the maximum tolerated dose (MTD) of capecitabine in the patients with nasopharyngeal carcinoma.
  
  
  METHODS
  Medical records of 36 patients with nasopharyngeal carcinoma treated with radiation and capecitabine were reviewed. The median dose of capecitabine was 1 600 mgx(m(2)xd)(-1) [700-2 500 mgx(m(2)xd)(-1)] orally for 2 weeks followed 1 week of rest and then another cycle. All the patients received a total dose ranging from 66 Gy to 74 Gy over 6-7.4 weeks.
  
  
  RESULTS
  In the 2 300 mgx(m(2)xd)(-1) group, Grade III toxicities observed were hang-foot syndrome (1 patient) and diarrhea (1 patient).
  
  
  CONCLUSIONS
  Concurrent administration of capecitabine and radiation were tolerable in the patients with nasopharyngeal carcinoma. The maximum tolerated dose is 2 300 mgx(m(2)xd)(-1), The recommended phase II dose is 1 700 mgx(m(2)xd)(-1) daily administered by this intermittent schedule.
authors.affiliation: Department of Nasopharyngeal Carcinoma, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, 510060, PR China.
authors.forename: Yong
authors.initials: Y
authors.lastname: Jiang
authors.forename: Ming-Huang
authors.initials: MH
authors.lastname: Hong
authors.forename: Man-Quan
authors.initials: MQ
authors.lastname: Deng
authors.forename: Ling
authors.initials: L
authors.lastname: Guo
authors.forename: Ka-Jia
authors.initials: KJ
authors.lastname: Cao
authors.forename: Hao-Yuan
authors.initials: HY
authors.lastname: Mo
authors.forename: Fang
authors.initials: F
authors.lastname: Qiu
authors.forename: Hai-Qiang
authors.initials: HQ
authors.lastname: Mai
authors.forename: Qiu-Yan
authors.initials: QY
authors.lastname: Chen
authors.forename: Rui
authors.initials: R
authors.lastname: Sun
authors.forename: Dong-Hua
authors.initials: DH
authors.lastname: Luo
authors.forename: Pei-Yu
authors.initials: PY
authors.lastname: Huang
mesh_terms: D000328:Adult; D000368:Aged; D000069287:Capecitabine; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000628:therapy*; D011879:Radiotherapy Dosage
chemical_list: D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil